- Home
- SVRE vs SCNI Comparison
SVRE vs SCNI Comparison
Compare SVRE & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRE
- SCNI
- Stock Information
- Founded
- SVRE 2014
- SCNI 2003
- Country
- SVRE Israel
- SCNI Israel
- Employees
- SVRE N/A
- SCNI N/A
- Industry
- SVRE
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SVRE
- SCNI Health Care
- Exchange
- SVRE Nasdaq
- SCNI Nasdaq
- Market Cap
- SVRE 2.8M
- SCNI 3.1M
- IPO Year
- SVRE 2022
- SCNI N/A
- Fundamental
- Price
- SVRE $0.88
- SCNI $3.51
- Analyst Decision
- SVRE
- SCNI
- Analyst Count
- SVRE 0
- SCNI 0
- Target Price
- SVRE N/A
- SCNI N/A
- AVG Volume (30 Days)
- SVRE 644.4K
- SCNI 8.1K
- Earning Date
- SVRE 08-27-2024
- SCNI 11-22-2024
- Dividend Yield
- SVRE N/A
- SCNI N/A
- EPS Growth
- SVRE N/A
- SCNI N/A
- EPS
- SVRE N/A
- SCNI 8.20
- Revenue
- SVRE $458,952.00
- SCNI $452,000.00
- Revenue This Year
- SVRE N/A
- SCNI N/A
- Revenue Next Year
- SVRE $422.52
- SCNI N/A
- P/E Ratio
- SVRE N/A
- SCNI $0.43
- Revenue Growth
- SVRE N/A
- SCNI N/A
- 52 Week Low
- SVRE $0.80
- SCNI $2.23
- 52 Week High
- SVRE $27.00
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- SVRE 42.74
- SCNI 52.75
- Support Level
- SVRE $0.80
- SCNI $3.41
- Resistance Level
- SVRE $0.94
- SCNI $3.80
- Average True Range (ATR)
- SVRE 0.10
- SCNI 0.18
- MACD
- SVRE 0.00
- SCNI -0.00
- Stochastic Oscillator
- SVRE 15.23
- SCNI 36.42
About SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The Company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road, and pedestrians.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.